The obtained1H NMR was based on the literature [24]. For the synthesis of honokiol epoxide, HNK (2.7 MHP 133 g, 10 mmol) was dissolved in dry dichloromethane (40 mL) from Sigma-Aldrich and the solution was cooled to 0 C followed by addition ofmeta-chloroperoxybenzoic acid (6.7 g, 40 mmol) from Sigma-Aldrich in portions over 30 minutes. exposure was attributable to transcriptional repression as well as proteasomal degradation. HNK-mediated suppression of AR protein was managed in LNCaP cells after knockdown of p53 protein. HNK-induced apoptosis was not affected by R1881 treatment. == CONCLUSIONS == The present study demonstrates, for the first time, that HNK inhibits activity of AR in prostate malignancy cells regardless of the p53 status. Keywords:Honokiol, Alternative medicine, Androgen receptor, MHP 133 Prostate malignancy == INTRODUCTION == Men with prostate malignancy experience substantial loss in quality of life from the disease and treatments. Despite a much deeper grasp of the prostate malignancy biology, this disease continues to be a leading cause of cancer-related deaths among men in western countries including the United States [1,2]. Effective and safer preventive interventions are needed to diminish morbidity and mortality in men with prostate malignancy. Plants used in complementary and option medicine are a rich source of phytochemicals potentially useful for prevention and treatment of cancers [35]. Honokiol (HNK) is usually one such small-molecule isolated from your bark ofMagnolia officinalis, and exhibits a variety of pharmacological properties includingin vivoanti-cancer MHP 133 effect [68]. For example, previous work from our own laboratory has revealedin vivogrowth inhibitory effect of orally administered HNK against PC-3 human prostate malignancy cells [9]. Bone metastatic growth of an androgen-independent human prostate malignancy cell collection (C4-2) was inhibited significantly by daily intraperitoneal administration of HNK, and this inhibitory effect was potentiated by docetaxel [10]. Thein vivoantitumor effect of cetuximab, an epidermal growth factor receptor inhibitor, was enhanced by HNK treatment in a human head and neck malignancy cell collection [11]. HNK increased the efficacy of other commonly used malignancy chemotherapeutic brokers such as cisplatin and gemcitabine [12,13]. Other notable anti-cancer effects of HNK include prevention of UVB-induced skin carcinogenesis, and inhibition of angiogenesis and metastasis [1416]. Significant progress has been made in our understanding of the mechanisms underlying anti-cancer effects of HNK [1720]. For instance, growth inhibitory effect of HNK in PC-3 and LNCaP human prostate malignancy cells was associated with G0G1phase cell cycle arrest due to suppression of E2F1 transcriptional activity [17]. In addition, HNK treatment caused apoptosis in human prostate malignancy cells in association with induction of proapoptotic proteins (Bax, Bak, and Bad) and down-regulation of anti-apoptotic proteins Bcl-xL and Mcl-1 [9]. Previous studies have shown that HNK administration to C4-2 tumor bearing mice causes a decrease in serum prostate specific antigen (PSA) level [10]. Because PSA is usually a well-accepted target of androgen receptor (AR), which plays an important role in prostate malignancy development and progression of the disease to castration-resistant state MHP 133 [21], it was of interest to determine if HNK inhibits AR activity. == MATERIALS AND METHODS == == Reagents == HNK (purity 98%) was purchased from LKT Laboratories (St. Paul, MN) whereas its analogs [honokiol dichloroacetate (HDCA), honokiol epoxide, and biseugenol] were synthesized as explained below. The stock solution of each compound was prepared in dimethyl sulfoxide (DMSO) at 50 mM concentration, and Ptprc diluted with culture media immediately before use. Final concentration of DMSO was 0.08%. The proteasomal inhibitor MG132 and anti-p53 antibody were purchased from Calbiochem-EMD Chemicals (Gibbstown, NJ); the 4,6-diamidino-2-phenylindole (DAPI), anti–tubulin antibody, and anti-actin antibody were purchased from Sigma-Aldrich (St. Louis, MO); and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from GeneTex (Irvine, CA). Synthetic androgen R1881 was a gift from Dr. Zhou Wang (Department of Urology, University or college of Pittsburgh, Pittsburgh, PA). Charcoal/dextran-treated fetal bovine serum (cFBS) was purchased from HyClone-Thermo Fisher Scientific (Waltham, MA); phenol red-free RPMI1640 medium, antibiotic combination, and phosphate-buffered saline (PBS) were from Invitrogen-Life Technologies (Grand Island, NY); and DMEM and heat-inactivated FBS were from Mediatech (Manassas, VA). Antibody against AR was from Santa Cruz Biotechnology (Dallas, TX). Anti-PSA antibody was purchased from Dako-Agilent Technologies (Carpinteria, CA). FuGENE 6, Dual-Luciferase Reporter Assay kit, and pRL-CMV vector were purchased from Promega (Madison, WI), whereas the pARLUC plasmid was a gift from Dr. William H. Walker (Department of Obstetrics, Gynecology and Reproductive Sciences, University or college of Pittsburgh, Pittsburgh, PA) [22]. Alexa Fluor MHP 133 488 goat anti-rabbit antibody was from Molecular Probes-Life Technologies. A control nonspecific siRNA and a p53-specific siRNA were purchased from Qiagen (Germantown, MD) and Santa Cruz Biotechnology, respectively. Anti-phospho-(S15)-p53 antibody was from Cell Signaling Technology (Danvers,.